An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs TNO 155 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 11 Jul 2017 Status changed from not yet recruiting to recruiting.
- 01 May 2017 Planned End Date changed from 11 Feb 2020 to 18 Mar 2020.
- 01 May 2017 Planned primary completion date changed from 11 Feb 2020 to 18 Mar 2020.